PATENT CLAIM ANALYSIS

Application Number: 16060559
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "184000"]

Abstract:
The present invention relates to novel monomaleimide-functionalized platinum compounds of formula (I), including in particular novel monomaleimide-functionalized oxaliplatin and carboplatin derivatives, as well as their use as medicaments, particularly for the treatment or prevention of cancer.

Claim (Index 46):
The compound for use according to any one of  claims 41  to  44  or the pharmaceutical composition for use according to any one of  claims 41  to  44 , wherein the compound or the pharmaceutical composition is to be administered in combination with one or more anticancer drugs selected from: an angiogenesis inhibitor which is preferably a protease inhibitor, a fibroblast growth factor receptor kinase inhibitor, or a vascular endothelial growth factor receptor kinase inhibitor; a cytostatic drug which is preferably an antimetabolite; an antimitotic agent which is preferably a microtubule-stabilizing drug or an antimitotic alkaloid; an anti-tumor antibiotic; an alkylating agent which is preferably a nitrogen mustard or a nitrosourea; an endocrine agent which is preferably an adrenocorticosteroid, an androgen, an anti-androgen, an estrogen, an anti-estrogen, an aromatase inhibitor, a gonadotropin-releasing hormone agonist, or a somatostatin analog; a compound that targets an enzyme or receptor that is overexpressed and/or otherwise involved in a specific metabolic pathway that is misregulated in the tumor cell, wherein said compound is selected from ATP and GTP phosphodiesterase inhibitors, histone deacetylase inhibitors, protein kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors, fibroblast growth factor inhibitors, insulin-like growth factor receptor inhibitors, PI3K inhibitors and platelet-derived growth factor receptor kinase inhibitors; an aminopeptidase inhibitor; a proteasome inhibitor; a cyclooxygenase inhibitor; a topoisomerase inhibitor; a poly ADP ribose polymerase (PARP) inhibitor; or an epidermal growth factor receptor (EGFR) inhibitor/antagonist.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 94.0
- Lexical Diversity: 1.2
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['10500516', '15093345', '14305643', '11691374', '15037941']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7642515092793685
- 35 USC 102 Novelty (BERT): 0.5114021949156353
- Combined Prediction Score: 0.7389665778429952
- Mean Citation Score: 284.677548
- Max Citation Score: 286.78967
- Similarity Product: 206.54925429235817

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test